KRAS Kickers

At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder. Personalized: KRAS G12D, CRC, US trials Results (in 4 minutes): 20 trials go to KRASHUB.ORG in beta - would love your feedback abstract asco.org/abstracts-pres… FYI: G12V - 8 trials for CRC G12R - 7 trials for CRC

What an impactful talk given by @KRASKickers @TerriConneran @cancerGRACE . She described her diagnosis as a “cancer circus “ not only Impacting her but her family and community. Her advice: - acknowledge - be present - safe words to Google - forgive self ❤️ you inspire me!

"Be here now, in the moment." @TerriConneran Thank you for this amazing presentation! #LungCancer #PatientAdvocate #KRAS #LungCancerSurvivor #TargetedTherapies #GRACE @KRASKickers

#KRASatAACR26 GNASR201C enhances peritoneal carcinomatosis in KRASG12D-driven gastrointestinal cancer models April 21 Saikat Chowdhury @jpshen_mD @UTMDAnderson abstractsonline.com/pp8/?fbclid=Iw… @AACR #EndCancer #KRAS #AACR26

#KRASatAACR26 1330 - Targeting Aurora kinase A for potentiating colorectal cancer to KRAS targeted therapy abstractsonline.com/pp8/?fbclid=Iw… April 19th @AACR #KRAS #AACR26

#RAS #revolution in first line chemo combo with gemcitabine and nab-paclitaxel backbone, the preview for ongoing registrational RASolute 303 study #KRAS #PDAC @MSK_DeptOfMed @MSKCancerCenter

🔬 Phase 1 expansion shows Varseta-M delivers notable response rates and manageable safety in heavily pretreated metastatic #ColorectalCancer, with FDA registrational planning underway. hubs.li/Q047jfhC0

Look at our fabulous LiveLung member and Champion, Lisa Haines! We love seeing our members spreading awareness and advocacy. Share a photo of yourself today and show how you’re making a difference this World Cancer Day! #WorldCancerDay #LungCancerAwareness #LungCancer #AdvocacyInAction #MemberSpotlight

#KRASatAACR26 LB407 / 7 - Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC) April 21 MiniSymposium: Late-Breaking Research abstractsonline.com/pp8/?fbclid=Iw… @AACR @CentralParkWMD @aparna1024 #KRAS #AACR26

Less than 2 months to @AACR! Thrilled to speak in the Major Symposium:RAS Inhibitors,Mechanisms of Resistance, & Drug Combinations. Grateful to the NextGen Stars Program for this opportunity. Looking forward to great science, connect with people & new collaborations. #AACR26

Colorectal cancer survivor's inspiring story: 30-year-old dad beats terminal diagnosis through pioneering immunotherapy trial. cbsnews.com/news/colon-can…

KRAS inhibitors have been used to treat pancreatic cancer, but can they PREVENT cancer from occurring altogether? In @ScienceMagazine from @PennCancer Cancer interception with KRAS inhibitors in preclinical models of #PancreaticCancer science.org/doi/10.1126/sc…

KRAShing #pancreaticcancer before takeoff | #cancerinterception science.org/doi/10.1126/sc…

Update to the UNICORN trial in ITALY. Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) Expansion 5 to 12 cohorts Still open: cohorts for HER2, POLE KRAS G12C cohorts w/ vorbipiprant +/- I/O AACR 25: aacrjournals.org/clincancerres/… cohorts w/ amivantamab UNICORN part II - Bot/Bal ASCO GI 2025 asco.org/abstracts-pres… #OncoAlert PI: @@FilippoPietran4

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study nature.com/articles/s4146… KRAS Cancer Clinical Trial Updates: What Patients Need to Know from ASCO 2025-June G12C Lung NSCLC Dr. Marina Garassino and @TerriConneran Update from the LOXO-RAS-20001 trial at 42 min youtube.com/watch?v=FT3yNI… @marinagarassino

"I just sat there & I cried for a minute. But then I had to go home and tell my husband I had stage 4 lung cancer." At 33, Wyatt was diagnosed w Stage 4 lung cancer. He joins us to share his journey through 8 lines of treatment Episode 1: youtu.be/5Ura3M1b1HM?si…

Next-generation KRAS G12C inhibitor olomorasib shows promising pan-tumor activity in a first-in-human study. ORR ~37% in non-CRC tumors with durable response. Activity even observed after prior KRAS G12C inhibitors. KRAS targeting keeps evolving. nature.com/articles/s4146…

🚨 Abstract submissions close on Sunday 15 March for the @CR_UK #PancreaticCancer Conference! 🚨 Submit your abstract now: cruk.ink/4b3o3ZF Apply for travel awards by Sunday 12 April. Find out more: cruk.ink/3PdYYTf

@dose_of_naz Recruiting at two sites: Puerto Rico & in Texas 234 international locatins listed.

NEW Ph3: SOC #Chemo + #Bevacizumab +/- #INCA33890 in 1L MSS #mCRC clinicaltrials.gov/study/NCT07284… #MedTwitter #Oncology #Incyte #ClinicalTrials #ColonCancer

Trial has opened up it's 12th site in Australia: A Phase 1/​2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors clinicaltrials.gov/study/NCT07020… KRAS Trials FB post with research links facebook.com/permalink.php?…

new KRAS inhibitor trial A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation to open in April 2026 phase 1, 145 pts clinicaltrials.gov/study/NCT07458… "KST-6051 is a potent and selective inhibitor of KRAS, with balanced activity against KRAS in the active (GTP-bound) and inactive (GDP-bound) states..." kestreltherapeutics.com/patients/